Healthcare ❯Pharmaceuticals ❯Drug Development
Phase 3 Trials Patient Outcomes Fast Track Designation by FDA Patient Care
Expected to close in the third quarter of 2025, the deal secures Lilly’s control of VERVE-102, a Fast Track–designated gene-editing therapy in Phase 1b trials.
